Chemical suppressors of neurotoxicity in synucleinopathic diseases
This invention relates to methods treating neurodegenerative alpha-synuclein aggregation diseases and disorders such as Parkinson's disease using compounds including glycyrrhetinic acid analogs, camptothecin and camptothecin analogs.